Review article: The opportunities and benefits of extended acid suppression

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue SUPPL. 2, 2006, Pages 23-34

  Scarpignato, C ^a   Pelosini, I ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZD 0865; BENATOPRAZOLE; BICARBONATE; CLARITHROMYCIN; ENZYME INHIBITOR; ESOMEPRAZOLE; IMIDAZONAPHTHYRIDINE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLONE; RABEPRAZOLE; REVAPRAZAN; SORAPRAZAN; STOMACH SECRETION INHIBITOR; TINIDAZOLE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM INJURY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STRUCTURE; GASTROESOPHAGEAL REFLUX; HALF LIFE TIME; HELICOBACTER INFECTION; HUMAN; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH DISEASE; UPPER GASTROINTESTINAL BLEEDING;

ANTACIDS; ANTI-ULCER AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL DISEASES; HUMANS; IMIDAZOLES; OMEPRAZOLE; PROTON PUMPS; PYRIDINES;

EID: 33748659033     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02945.x     Document Type: Conference Paper

References (100)

1. Bardhan KD, Williamson M, Royston C, Lyon C. Admission rates for peptic ulcer in the trent region, UK, 1972-2000. Changing pattern, a changing disease? Dig Liver Dis 2004; 36: 577-88.
2. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433-40.
3. Tytgat GN. Are there unmet needs in acid suppression? Best Pract Res Clin Gastroenterol 2004; 18 (Suppl.): 67-72.
4. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 10-9.
5. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16: 441-3.
6. Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994; 89: 509-12.
7. Orr WC. Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 2005; 17: 113-20.
8. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 2005; 18: 370-3.
9. 2-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol 2001; 15: 355-70.
10. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
11. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118 (Suppl. 1): S9-S31.
12. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion 2003; 67: 1-5.
13. Freston JW, Chiu YL, Mulford DJ, Ballard ED. Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 361-7.
14. Baldi F, Ghersi S, Cavoli C, Torresan F. A comparison of the new lansoprazole orally disintegrating tablets (LODT) tablets with esomeprazole in patients with non erosive reflux disease. Gastroenterology 2005; 128 (Suppl. 2): A523-524.
15. Anonymous Omeprazole/Antacid-powder suspension-Santarus: omeprazole/sodium bicarbonate powder-Santarus, SAN 05. Drugs R&D 2004; 5: 349-50.
16. Howden CW. Review article: immediate-release proton-pump inhibitor therapy-potential advantages. Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 25-30.
17. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 21: 1467-74.
18. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother 2005; 6: 2501-10.
19. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294-307.
20. ClinicalTrials.gov. Ongoing Trials with AZD0865 (http://www. clinicaltrials.gov/).
21. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
22. Tutuian R, Castell DO. Nocturnal acid breakthrough - approach to management. MedGenMed 2004; 6: 11 [http://www.medscape.com/viewarticle/490723].
23. Anonymous Tenatoprazole. Benatoprazole, TU 199. Drugs RD 2002; 3: 276-7.
24. +-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol 1999; 21: 115-22.
25. +-ATPase in vitro and in vivo. Biochem Pharmacol 2006; 71: 837-49.
26. +)-ATPase by proton pump inhibitors. J Am Chem Soc 2004; 126: 7800-11.
27. Waldum HL, Lehy T, Brenna E, et al. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol 1991; 26: 23-35.
28. Kakinoki B, Ono C, Yamazaki N, et al. General pharmacological properties of the new proton pump inhibitor (±)-5-methoxy-2-[[(4-methoxy-3,5- dimethyl pyrid-2-yl)methyl]sulfi-nyl]-1H-imidazo [4,5-b]pyridine. Methods Find Exp Clin Pharmacol 1999; 21: 179-87.
29. +-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol 1999; 51: 457-64.
30. Domagala F, Ficheux H, Houin G, Barré J. Pharmacokinetics of tenatoprazole, a newly synthesised proton pump inhibitor, in healthy male Caucasian volunteers. Arzneimittelforschung 2006; 56: 33-39.
31. Welage LS, Karlstadt RG, Burton MS, Lynn RB. Pharmacokinetic comparison of five proton pump inhibitors. Gastroenterology 2002; 122 (4 Suppl.): A202.
32. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
33. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 2002; 58: 453-8.
34. Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004; 19: 655-62.
35. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005; 21: 575-82.
36. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100: 1949-56.
37. Miner PB Jr, Katz PO, Chen Y, Sostek M. Gastric Acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
38. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GORD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
39. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
40. Chey W, Huang B, Jackson RL. Lansoprazole and esomeprazole in symptomatic GORD: a double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clinical Drug Invest 2003; 23: 69-84.
41. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16: 1309-16.
42. Ours TM, Fackler WK, Richter JE, Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98: 545-50.
43. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18: 1091-8.
44. 2 blockers improve nocturnal gastric acid control in GORD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
45. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
46. Cross LB, Justice LN. Combination drug therapy for gastroesophageal reflux disease. Ann Pharmacother 2002; 36: 912-6.
47. 2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2004; 4: CD004275.
48. Scarpignato C, Pelosini I, Molina E. Acid suppression in Barrett's esophagus: why and how? In: Giuli R, Siewert JR, Couturier D, Scarpignato C, eds. Barrett's Esophagus. 250 Questions, 250 Answers Vol. 2. Paris: John Libbey Eurotext, 2003: 437-55.
49. Sharma P. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma? Am J Med 2004; 117 (Suppl. 5A): 79S-85S.
50. Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 2004; 22: 171-80.
51. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432-4.
52. Plachetka J, Morelli G, Hines C, et al. Integrated gastric acidity can predict the prevention of naxopren-induced gastroduodenal pathology in normal subjects. Gastroenterology 2003; 124 (Suppl. 1): A510.
53. Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal antiinflammatory drug-induced gastroduodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol 1999; 31 (Suppl. 1): S63-72.
54. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996; 156: 2321-32.
55. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, Di Mario F. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924-36.
56. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
57. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948.
58. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26.
59. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-34.
60. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal antiinflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169-75.
61. Davis NM, Skojdt NM. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin Pharmacokinet 2000; 38: 377-92.
62. Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am 1993; 22: 127-39.
63. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949-58.
64. Bazzoli F, BianchiPorro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002; 34: 70-83.
65. Malfertheiner P, Mégraud F, O'Morain C, et al. Current Concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
66. Malfertheiner P, Megraud F, O'Morain C. The Maastricht 3 Consensus Report: Guidelines for the Management of Helicobacter pylori infection. Eur Gastroenterol Rev 2005; 59-62 [available at http://www.helicobacter.org/down- load/ summary_guidelines_hp_infection% 20_business_briefing.pdf].
67. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
68. Scarpignato C, Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Progr Basic Clin Pharmacol 1999; 11: 136-80.
69. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 2004; 36: 243-7.
70. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21-7.
71. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): 56-60.
72. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
73. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-9.
74. Parkman HP, Urbain JL, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998; 42: 243-50.
75. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther 1996; 10: 105-9.
76. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
77. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther 2003; 18: 93-100.
78. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter 2002; 7: 331-6.
79. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. J Clin Gastroenterol 2004; 38: 503-6.
80. Gillen D, Wirz AA, McColl KEL. Esomeprazole 40 mg BID produces profound 24 h acid suppression with minimal acid breakthrough. Gastroenterology 2003; 124 (Suppl. 1): A231.
81. Gralnek IM, Jensen DM, Gornbein J, et al. Clinical and economic outcomes of individuals with severe/peptic ulcer hemorrhage and a nonbleeding visible vessel: an analysis of two prospective clinical trials. Am J Gastroenterol 1998; 93: 2047-56.
82. Andriulli A, Annese V, Caruso N, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol 2005; 100: 207-19.
83. Berstad A. Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? Scand J Gastroenterol 1997; 32: 396-8.
84. Geun WP. Are there indications for intravenous acid inhibition in the prevention and treatment of upper GI bleeding? Scand J Gastroenterol 2000; 35 (Suppl. 232): 10-20.
85. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. Gastroenterology 1978; 74: 38-43.
86. Patchett SE, Enright H, Afdhal N, O'Connell W, O'Donoghue DP. Clot lysis by gastric juice: an in vitro study. Gut 1989; 30: 1704-7.
87. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001; 35: 1528-34.
88. 2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15: 917-26.
89. 2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16: 1137-42.
90. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer haemorrhage: a 'meta-analysis'. Aliment Pharmacol Ther 2000; 14: 1119-26.
91. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568.
92. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay-results from the Cochrane Collaboration. Aliment Pharmacol Ther 2005; 22: 169-74.
93. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21: 677-86.
94. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol 2005; 20: 11-25.
95. Metz D, Amer F, Hunt B. Establishing a regimen for lansoprazole administration to markedly inhibit acid output in normal volunteers. Gastroenterology 2005; 129: A370 [abstract].
96. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003; 18: 705-11.
97. Scarpignato C, Pelosini I, Di Mario I. Acid suppression therapy: where do we go from here? Dig Dis 2006; 24: 11-46.
98. Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003; 63: 1785-97.
99. Bentley R. Role of sulfur chirality in the chemical processes of biology. Chem Soc Rev 2005; 34: 609-24.
100. Charbit S, Cohen A, Ficheux H, Homerin M, Schutze F, Taccoen A. Enantiomer (-) of Tenatoprazole and the Therapeutic Use Thereof. Patent No. WO060891, 2004.